research use only
Cat.No.S7653
| Related Targets | EGFR VEGFR JAK FGFR PDGFR Src HIF HER2 FLT3 FLT |
|---|---|
| Other FAK Inhibitors | Defactinib (VS-6063) PF-562271 (VS-6062) PF-573228 PF-562271 HCl PF-562271 Besylate TAE226 (NVP-TAE226) GSK2256098 PF-431396 Y15 Ifebemtinib (IN10018, BI-853520) |
|
In vitro |
DMSO
: 100 mg/mL
(199.4 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about VS-4718 (PND-1186) solubility in DMSO or water
Read more about VS-4718 (PND-1186) working concentrations for cell culture treatment
VS-4718 (PND-1186) is a potent inhibitor of FAK (21870 nM), PYK2, FLT3. VS-4718 (PND-1186) exhibits the greatest inhibitory potency toward FAK (IC50 = 21870 nM).
| Information | VS-4718 (PND-1186) is a potent, selective, and reversible ATP-competitive FAK inhibitor. It affects FAK/Src and PI3K/Akt signaling, by binding to the kinase domain and blocking FAK autophosphorylation at Tyr397, inhibiting tumor cell proliferation, migration, and invasion. |
|---|---|
|
Read more about VS-4718 (PND-1186) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
| Molecular Weight | 501.5 | Formula | C25H26F3N5O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1061353-68-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | SR-2156 | Smiles | CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC | ||
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
Whether the in vivo formulation of this compound using 2% DMSO+30% PEG 300+5% Tween 80+ddH2O is suitable for injection?
Answer:
A clear solution with the highest concentration at 5 mg/ml can be generated using the formulation: 2% DMSO + 30% PEG 300 + 5% Tween 80 + ddH₂O. It may be suitable for oral administration or injection.